CTIC Share Price

Open 4.18 Change Price %
High 4.25 1 Day 0.07 1.69
Low 4.11 1 Week -0.05 -1.17
Close 4.22 1 Month 0.31 7.93
Volume 48733 1 Year 3.77 837.78
52 Week High 6.48
52 Week Low 0.31
CTIC Important Levels
Resistance 2 4.35
Resistance 1 4.30
Pivot 4.19
Support 1 4.14
Support 2 4.09
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
FTR 1.46 12.31%
FTR 1.46 12.31%
SUSQ 14.20 -0.77%
CSCO 31.21 -0.54%
More..
NASDAQ USA Top Gainers Stocks
CPSL 0.08 60.00%
LOCM 0.09 50.00%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
CMLS 0.49 25.64%
OTT 2.39 25.13%
EVEP 1.30 18.18%
ARNA 1.33 15.65%
INVE 5.72 14.86%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
ULTR 0.05 -37.50%
More..

Cell Therapeutics, Inc. (NASDAQ: CTIC)

CTIC Technical Analysis 3
As on 19th May 2017 CTIC Share Price closed @ 4.22 and we RECOMMEND Buy for LONG-TERM with Stoploss of 2.06 & Buy for SHORT-TERM with Stoploss of 4.18 we also expect STOCK to react on Following IMPORTANT LEVELS.
CTIC Target for May
1st Target up-side 4.53
2nd Target up-side 4.76
3rd Target up-side 5
1st Target down-side 3.85
2nd Target down-side 3.62
3rd Target down-side 3.38
CTIC Other Details
Segment EQ
Market Capital 134819600.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.celltherapeutics.com
CTIC Address
CTIC
3101 Western Avenue
Suite 600
Seattle, WA 98121
United States
Phone: 206-282-7100
Fax: 206-284-6206
CTIC Latest News
Interactive Technical Analysis Chart Cell Therapeutics, Inc. ( CTIC NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Cell Therapeutics, Inc.
CTIC Business Profile
Cell Therapeutics, Inc. (CTI) is a biopharmaceutical company focused on the acquisition, development, and commercialization of less toxic ways to treats cancer. The Company is concentrating its efforts on treatments that target blood-related cancers where there is an unmet medical need. The Company is primarily focused on commercializing PIXUVRI (pixantrone) in the European Union for multiplies relapsed or refractory aggressive non-Hodgkin lymphoma (NHL), and conducting a Phase III clinical trial of pacritinib for the treatment of myelofibrosis. PIXUVRI is a novel aza-anthracenedione derivative that is structurally related to anthracyclines and anthracenediones, but does not appear to be associated with the same level of cardiotoxic effects.